- Timosaponin A1
-
- $0.00 / 20mg
-
2023-02-24
- CAS:68422-00-4
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Sarsasapogenin 3-O-β-D-galactopyranosid Basic information |
| Product Name: | Sarsasapogenin 3-O-β-D-galactopyranosid | | Synonyms: | Sarsasapogenin 3-O-β-D-galactopyranosid;TiMosaponin A1;Timosaponin AI;Sarsasapogenin 3-O-β-D-galactopyranoside;β-D-Galactopyranoside, (3β,5β,25S)-spirostan-3-yl;Sarsasapogenin 3-O-β-D-galactopyranosid USP/EP/BP;Sarsasapogenin 3-O-β-D-galactopyranoside;Sarsasapogenin 3-O-β-D-galactopyranosid | | CAS: | 68422-00-4 | | MF: | C33H54O8 | | MW: | 578.79 | | EINECS: | | | Product Categories: | | | Mol File: | 68422-00-4.mol |  |
| | Sarsasapogenin 3-O-β-D-galactopyranosid Chemical Properties |
| Boiling point | 695.5±55.0 °C(Predicted) | | density | 1.26±0.1 g/cm3 (20 ºC 760 Torr) | | solubility | DMSO: 10 mM | | form | A solid | | pka | 12.91±0.70(Predicted) |
| | Sarsasapogenin 3-O-β-D-galactopyranosid Usage And Synthesis |
| Uses | Timosaponin A1 exhibits a wide spectrum of bioactivities. Also, it is a metabolite of Timosaponin A3 (T444695), which suppresses certain human tumor processes and has the potential to be developed as an anticancer agent. Reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Induction of mitochondrial-dependent apoptosis in HepG2 human hepatocellular carcinoma cells.Timosaponin A3 is a potent inhibitor of U46619, that induces rat platelet aggregation and exhibited superior selectivity for the TP receptor vs. other G protein-coupled receptors and a PKC activator. |
| | Sarsasapogenin 3-O-β-D-galactopyranosid Preparation Products And Raw materials |
| Raw materials | 1-[(3S,5R,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9, 11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone-->Sarsasapogenin-->IPTG-->pseudoprototimosaponin AIII |
|